The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Kristin Ferguson named senior director of ACCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Kristin Ferguson was named senior director of cancer care delivery and health policy at the Association of Community Cancer Centers.

Ferguson will lead the organization’s initiatives to improve cancer care delivery across rural, urban, and under-resourced settings, and will also provide support and resources to members of the oncology workforce, working to reshape reimbursement to better meet the needs of patients and providers.

Ferguson most recently served as clinical operations manager for the Lombardi Comprehensive Cancer Center at Medstar Georgetown University Hospital. There, Ferguson oversaw the daily operations of the clinic, ensured services met hospital and ONS standards, and monitored patient data collection, quality of care, and trends in clinical growth.

Ferguson has served as a voice for nursing and oncology in many policy-making forums, including the ONS Millennial Advisory Panel, the Oncology Nursing Society Congress Planning Team, AACN/ GNSA Policy Committee, Cancer Moonshot Summit and the Biden Cancer Summit town Hall. She has also advised and participated on research teams and is a member of an NINR Funded Research Team at Georgetown University on a grant to research symptom clusters in oncology patients.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account